Name: Triapine (3-AP)
Brand: Selleck Chemicals
SKU: S7470
Rating: 5 (18 reviews)

Springe zu

Qualitätskontrolle (Quality Control)

Charge: Reinheit: 99.92%

99.92

Verwandte Ziele	HDAC PARP ATM/ATR DNA-PK WRN Topoisomerase PPAR Sirtuin Casein Kinase eIF
Weitere DNA/RNA Synthesis Inhibitoren	CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) EED226 RK-33 BMH-21 Carmofur YK-4-279 Halofuginone Tegafur (FT-207)

Zellkultur, Behandlung & Arbeitskonzentration
(Cell Culture, Treatment & Working Concentration)

Zelllinien	Assay-Typ	Konzentration	Inkubationszeit	Aktivitätsbeschreibung	PMID
SK-N-MC	Antiproliferative assay			Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50=0.31μM	17142046
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50=0.26μM	17602603
SK-N-MC	Antiproliferative assay			Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50=0.54μM	17963372
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	18159922
KB-3-1	Cytotoxicity assay		72 hrs	Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay, IC50=1.4μM	19397322
KB-3-1	Cytotoxicity assay		72 hrs	Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay, IC50=1.41254μM	19397322
KBV1	Cytotoxicity assay		72 hrs	Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay, IC50=5.88844μM	19397322
KBV1	Cytotoxicity assay		72 hrs	Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay, IC50=5.9μM	19397322
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50=0.26μM	19601577
HCT116	Dark cytotoxicity assay		96 hrs	Dark cytotoxicity against human HCT116 cells expressing wild type p53 after 96 hrs by MTT assay, IC50=1.226μM	24900837
HCT116	Photocytotoxicity assay		24 hrs	Photocytotoxicity against human HCT116 cells expressing wild type p53 incubated for 24 hrs followed by light irradiation measured after 24 hrs by MTS assay in presence of ALA and FeCl3	24900837
HCT116	Function assay	4 uM	24 hrs	Induction of ROS generation in human HCT116 cells expressing wild type p53 at 4 uM after 24 hrs by spectrophotometry	24900837
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	27336684
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	27336684
KB-3-1	Cytotoxicity assay		72 hrs	Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay, IC50=3.1μM	27336684
KBC1	Cytotoxicity assay		72 hrs	Cytotoxicity against human KBC1 cells incubated for 72 hrs by MTT assay, IC50=8.9μM	27336684
SW480	Function assay	2.5 uM	48 hrs	Induction of morphological changes in human SW480 cells assessed as induction of massive cell flattening at 2.5 uM incubated for 48 hrs by phase contrast microscopy	27336684
HL60	Function assay	1 and 5 uM	30 mins	Induction of intracellular ROS generation in human HL60 cells at 1 and 5 uM in presence of CuCl2 incubated for 30 mins by DCF-DA staining based fluorescence assay	27336684
L1210	Growth inhibition assay			Growth inhibition of mouse L1210 cells by MTS assay, IC50=1.3μM	30904782
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	31614257
WPMY-1	Antiproliferative assay		72 hrs	Antiproliferative activity against human WPMY-1 cells assessed as reduction in cell proliferation incubated for 72 hrs by MTT assay, IC50=4.96μM	31614257
GES-1	Antiproliferative assay		72 hrs	Antiproliferative activity against human GES-1 cells assessed as reduction in cell proliferation incubated for 72 hrs by MTT assay, IC50=5.6μM	31614257
HEK293	Cytotoxicity assay			Cytotoxicity against HEK293 cells (CO-ADD:MA_007); CC50 by cell viability assay in DMEM (10% FBS) media using TC plates, by Resazurin F(560/590), CC50=2.827μM	ChEMBL
GES-1	Cytotoxicity assay		72 hrs	Cytotoxicity against human GES-1 cells after 72 hrs by MTT assay, IC50=5.4μM	ChEMBL
MGC803	Antiproliferative assay		72 hrs	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay, IC50=9.68μM	ChEMBL
MCF7	Antiproliferative assay		72 hrs	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50=18.85μM	ChEMBL
SMMC7721	Antiproliferative assay		72 hrs	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay, IC50=42.81μM	ChEMBL
Klicken Sie hier, um weitere experimentelle Daten zu Zelllinien anzuzeigen

Chemische Informationen, Lagerung & Stabilität (Chemical Information, Storage & Stability)

Molekulargewicht	195.24	Formel	C₇H₉N₅S	Lagerung (Ab dem Eingangsdatum)	3 Jahre-20°CPulver
CAS-Nr.	200933-27-3	SDF herunterladen		Lagerung von Stammlösungen	1 Jahr-80°Cin Lösungsmittel 1 Monat-20°Cin Lösungsmittel

Löslichkeit (Solubility)

In vitro
Charge:

DMSO : 39 mg/mL (199.75 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 39 mg/mL (199.75 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 39 mg/mL (199.75 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molaritätsrechner

Masse	Konzentration	Volumen	Molekulargewicht
=	×	×

Verdünnungsrechner Molekulargewichtsrechner

In vivo Charge:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Von Selleck Labs validiert. Sollten Sie Anpassungen an dieser Formulierung benötigen, kontaktieren Sie unser Verkaufsteam für kundenspezifische Tests.	1.250mg/ml (6.40mM)	Taking the 1 mL working solution as an example, add 50 μL 25 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In-vivo-Formulierungsrechner (Klare Lösung)

Schritt 1: Geben Sie die untenstehenden Informationen ein (Empfohlen: Ein zusätzliches Tier zur Berücksichtigung von Verlusten während des Experiments)

Dosierung: mg/kg Durchschnittsgewicht der Tiere: g Dosiervolumen pro Tier:μL Anzahl der Tiere:

Schritt 2: Geben Sie die In-vivo-Formulierung ein (Dies ist nur der Rechner, keine Formulierung. Bitte kontaktieren Sie uns zuerst, wenn es im Abschnitt "Löslichkeit" keine In-vivo-Formulierung gibt.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Berechnungsergebnisse:

Arbeitskonzentration: mg/ml;

Methode zur Herstellung der DMSO-Stammlösung: mg Wirkstoff vorgelöst in μL DMSO ( Konzentration der Stammlösung mg/mL, Bitte kontaktieren Sie uns zuerst, wenn die Konzentration die DMSO-Löslichkeit der Wirkstoffcharge überschreitet. )

Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügenμL PEG300, mischen und klären, dann hinzufügenμL Tween 80, mischen und klären, dann hinzufügen μL ddH₂O, mischen und klären.

Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügen μL Maisöl, mischen und klären.

Hinweis: 1. Bitte stellen Sie sicher, dass die Flüssigkeit klar ist, bevor Sie das nächste Lösungsmittel hinzufügen.
2. Achten Sie darauf, das/die Lösungsmittel der Reihe nach hinzuzufügen. Sie müssen sicherstellen, dass die bei der vorherigen Zugabe erhaltene Lösung eine klare Lösung ist, bevor Sie mit der Zugabe des nächsten Lösungsmittels fortfahren. Physikalische Methoden wie Vortex, Ultraschall oder ein heißes Wasserbad können zur Unterstützung des Lösens verwendet werden.

Wirkmechanismus (Mechanism of Action)

Targets/IC₅₀/Ki	Ribonucleotide reductase
In vitro	Triapine (3-AP) potently inhibits the activity of ribonucleotide reductase in both wild-type KB and HU-resistant KB nasopharyngeal carcinoma cells, and shows broad spectrum antitumor activity by inhibiting DNA synthesis in a series of cancer cell lines. In vitro, it blocks ischemic neurotoxicity and hypoxic toxicity with EC50 of 0.35 μM and 0.75 μM, respectively. This compound also shows its neuroprotective activity by suppressing cell death induced by neurotoxic agents, including staurosporine, veratridine and glutamate.
Kinase-Assay	Ribonucleotidreduktase-Assay
Kinase-Assay	Die CDP-Reduktase wird mittels Dowex 1-Borat-Ionenaustauschchromatographie bestimmt. Das Assay-Gemisch enthält 0,02 μCi [¹⁴C]CDP (52,9 mCi/mmol), 3 mM Dithiothreitol, 6 mM MgCl₂, 30 mM HEPES, 5 mM ATP, 0,15 mM unmarkiertes CDP und 10 μL Zellextrakt in einem Endvolumen von 0,02 mL. Die Inkubationszeit für die Reaktion beträgt 60 min, während dieser Zeit ist die Reaktion linear.
In vivo	In mice bearing the L1210 leukemia, Triapine (3-AP) (1.25 to 20 mg/kg) is curative for some mice without lethal toxicity. This compound also inhibits the growth of solid tumors in mice M109 lung carcinoma and human A2780 ovarian carcinoma xenografts. In addition, its combination with various classes of agents that damage DNA results in synergistic inhibition of the L1210 leukemia. In a rat model of transient ischemia, it reduces infarct volume by 59% when administered i.c.v. (50 μ per rat) and by 35% when administered i.v. (1 mg/kg).
Literatur	[1] https://pubmed.ncbi.nlm.nih.gov/10692563/ [2] https://pubmed.ncbi.nlm.nih.gov/16834759/

Anwendungen (Applications)

Methoden	Biomarker	Bilder	PMID
Western blot	p-Chk1 / Chk1 / p-CDK1/2 / CDK1/2 / p-H1		24413181
Growth inhibition assay	Cell viability		31118677

Klinische Studieninformationen (Clinical Trial Information)

(Daten von https://clinicaltrials.gov, aktualisiert am 2024-05-22)

NCT-Nummer	Rekrutierung	Erkrankungen	Sponsor/Kooperationspartner	Startdatum	Phasen
NCT00293345	Completed	Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Primary Central Nervous System Hodgkin Lymphoma\|Primary Central Nervous System Non-Hodgkin Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Adult T-cell Leukemia/Lymphoma\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Mycosis Fungoides/Sezary Syndrome\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Adult T-cell Leukemia/Lymphoma\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Mycosis Fungoides/Sezary Syndrome\|Stage IV Small Lymphocytic Lymphoma\|Unspecified Adult Solid Tumor Protocol Specific\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	June 2006	Phase 1

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Triapine (3-AP) DNA/RNA Synthesis Inhibitor

Molekulargewicht: 195.24

Qualitätskontrolle (Quality Control)

Zellkultur, Behandlung & Arbeitskonzentration
(Cell Culture, Treatment & Working Concentration)

Chemische Informationen, Lagerung & Stabilität (Chemical Information, Storage & Stability)

Löslichkeit (Solubility)

Molaritätsrechner

In-vivo-Formulierungsrechner (Klare Lösung)

Wirkmechanismus (Mechanism of Action)

Anwendungen (Applications)

Klinische Studieninformationen (Clinical Trial Information)

Triapine (3-AP) DNA/RNA Synthesis Inhibitor

Molekulargewicht: 195.24

Qualitätskontrolle (Quality Control)

Zellkultur, Behandlung & Arbeitskonzentration (Cell Culture, Treatment & Working Concentration)

Chemische Informationen, Lagerung & Stabilität (Chemical Information, Storage & Stability)

Löslichkeit (Solubility)

Molaritätsrechner

In-vivo-Formulierungsrechner (Klare Lösung)

Wirkmechanismus (Mechanism of Action)

Anwendungen (Applications)

Klinische Studieninformationen (Clinical Trial Information)

Zellkultur, Behandlung & Arbeitskonzentration
(Cell Culture, Treatment & Working Concentration)